Gilead Sees Room For Trodelvy In European Markets
Triple-Negative Breast Cancer Claim Clears CHMP
Executive Summary
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.